Participants will be randomly assigned to receive either the study drug at one of three dose levels or the placebo, and neither the participants nor the study staff will know which treatment is given. Over the course of several weeks, blood samples will be taken to assess clotting using tests such as aPTT (a test that measures how quickly blood forms a clot) and PT/INR (another test that evaluates clotting time). Heart health will be checked with a 12-lead ECG (a recording of the heart’s electrical activity). Safety will be monitored by recording any side effects, reviewing laboratory results, vital signs, and physical examinations.

Participants are randomly assigned to receive either the study drug at two possible doses or the placebo, and neither the participants nor the study staff know which treatment is given. Over 52 weeks, participants attend regular clinic visits where safety is checked through physical exams, vital signs, weight measurements, and questionnaires about mood. Cognitive and functional abilities are measured using the clinical dementia rating – sum of boxes, a score that reflects the severity of dementia, and the integrated Alzheimer’s disease rating scale, a test that looks at memory and daily tasks. Blood samples are taken to assess proteins linked to Alzheimer’s, such as p-Tau217 (a form of tau protein), amyloid β-protein Aβ40 and Aβ42 (building blocks of plaque), as well as markers of nerve damage (neurofilament light chain) and brain inflammation (glial fibrillary acidic protein). Brain imaging includes a size‑measuring scan called volumetric magnetic resonance imaging and a special scan that visualizes amyloid plaques known as amyloid positron emission tomography. All data are collected to evaluate whether the medication is safe and whether it helps preserve thinking and daily abilities.

Participants will be randomly assigned to receive either the active tablet or the placebo for a period of 12 weeks. During this time, regular visits will be scheduled to check weight, waist size, and basic blood tests, and to monitor heart rhythm using an ECG. Side effects, referred to as adverse events, will be recorded, and blood samples will be taken to study the drug’s pharmacokinetics, which describes how the medication is absorbed, distributed, and cleared from the body.

The purpose of the study is to evaluate how long the disease remains controlled after receiving the drug. Participants will receive a series of intravenous infusions of the medication, with each infusion given a few weeks apart. Throughout the trial, blood tests will measure PSA (a protein that indicates prostate cancer activity), and imaging scans such as a special scan that shows PSMA activity (PSMA PET/CT) and a scan that measures radiation dose to the tumor (SPECT/CT) will be performed to track tumor changes. Standard imaging criteria (RECIST) are used to assess whether tumors shrink, stay the same, or grow.

After the treatment phase, patients are followed for several months with regular check‑ups, blood tests, and scans to monitor disease status, side effects, pain levels, and overall well‑being. The study records how long patients live without the disease getting worse, as well as any improvements in symptoms or quality of life.

Participants will receive the assigned sedation during their colonoscopy and will be asked to complete a short questionnaire after the procedure to report how satisfied they felt. The study will also record how much medication was used, how long the procedure and recovery lasted, and any side effects or problems that occur. After the colonoscopy, participants will be monitored until they are fully awake and able to go home, and the overall success of completing the procedure will be noted.

The purpose of the study is to determine whether oral semaglutide leads to greater weight loss compared with the placebo when combined with diet and exercise. Participants will take the assigned tablet every day for several months, attend regular clinic visits where their weight, waist size, blood pressure, and blood tests are checked, and report any side effects. The study will track changes in body weight and related health measures over the course of the trial.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

The purpose of the trial is to find out whether adding pramipexole to the usual treatment can reduce anhedonia more effectively than placebo over a period of six weeks. Participants will be randomly assigned to receive either the active medication or the placebo, and neither the participants nor the study staff will know which is which (this is called a double‑blind design). Throughout the study, participants will visit the clinic several times for brief checks, and they will keep taking the tablets every day.

After the initial six‑week period, participants may be offered an open‑label follow‑up where everyone receives the active medication for up to 15 additional weeks. During the trial, simple tools such as questionnaires about mood and activity levels will be used, and some participants may undergo brain imaging with fMRI to explore how the drug affects brain activity. Safety will be monitored by asking about side effects and checking for any signs of mood changes.

The purpose of the trial is to determine whether this drug combination is safe and shows early signs of shrinking tumors. Participants take the tablet each day and receive the infusion every few weeks for several months, with regular doctor visits, blood tests, and imaging scans to watch for side effects and changes in tumor size. In the first part of the study, doctors find the highest dose that most people can tolerate (maximum tolerated dose) and choose a dose for later testing (recommended Phase II dose). In the second part, they look at how many patients experience a complete response (tumor disappears), partial response (tumor shrinks), stable disease (tumor does not grow), or progressive disease (tumor grows) after about six months.

The purpose of the study is to assess how safe the new injection is and how it changes the activity of a clotting protein called factor XI (FXI) over a 16‑week period. Participants will be randomly assigned to receive one of two hidden doses of the injection or the placebo, and all will receive the open‑label tablet. Visits will include simple blood draws to measure FXI activity and routine safety checks such as checking for bleeding or other side effects.

Throughout the trial, researchers will watch for any bleeding events, record any adverse experiences, and perform standard laboratory tests and vital‑sign measurements. Blood samples will also be taken at several time points to see how the drug behaves in the body and whether the immune system produces any antibodies against it.

During the trial, participants will take the study medication once daily for about 24 weeks. They will attend regular clinic visits where blood samples are drawn to measure hormone levels and safety checks are performed. The study follows a straightforward schedule of visits and tests, allowing researchers to observe changes in hormone levels over time without requiring any invasive procedures.

The purpose of the study is to determine whether ALKS 2680 can reduce daytime sleepiness in adults with Narcolepsy Type 1. Participants will be randomly assigned to receive either the study drug or a placebo for about twelve weeks. During the study, they will complete a questionnaire called the Epworth Sleepiness Scale that asks how likely they are to fall asleep in everyday situations, and they will take a short test called the Maintenance of Wakefulness Test that measures how long they can stay awake when asked to do so. Their episodes of cataplexy will also be recorded each week.

Throughout the trial, researchers will monitor participants for any side effects and will collect the questionnaire and test results to evaluate the safety and effectiveness of the medication. The collected information will help decide if the drug provides a beneficial option for managing the symptoms of this sleep disorder.

The purpose of the study is to determine whether adding ALXN2220 to eplontersen improves the ability to exercise compared with eplontersen plus placebo. To assess this, participants will perform a cardiopulmonary exercise test (CPET), a breathing and exercise test that measures the maximum amount of oxygen the body can use during intense activity. The test will be done at the start of the study and again after about a year of treatment.

During the trial, participants will visit the clinic regularly for the subcutaneous injections, the intravenous infusions, and safety checks such as blood tests and heart examinations. The study will continue for roughly 52 weeks, with scheduled appointments to monitor how the heart is working and to record any side effects. All procedures are designed to follow standard safety guidelines.

The purpose of the study is to reduce the maximum pain experienced during the procedure. Participants receive the injection shortly before the abortion is performed and then follow the standard medical abortion process. Throughout the procedure, pain levels are recorded using a visual analog scale, which is a simple line where a mark indicates how strong the pain feels, allowing researchers to compare the two groups.

The purpose is to find out how safe the medicines are and whether they can lower the activity of the cancer. Adults whose disease has returned after earlier therapy (relapsed) or does not respond to usual medicines (refractory) will receive the study drugs for several treatment cycles. Participants will have regular doctor visits, blood tests, and scans to watch for side effects and to see if the cancer shrinks. Terms like “biomarker‑selected” mean that a laboratory test is used to choose patients whose cancer has a specific characteristic; “dose limiting toxicity” describes side effects that stop the dose from being increased; and “overall response rate” is the percentage of patients whose cancer gets smaller or disappears.

The main aim of the study is to evaluate how safe and well‑tolerated multiple doses of the medicine are in this patient group. Participants will receive a series of injections over several weeks, with regular clinic visits where vital signs, heart rhythm checks, and blood tests are performed to watch for any unwanted effects. Some participants may receive a harmless inactive substance for comparison, but the study staff will not know which person receives which treatment.

During the study period, blood samples are taken to measure the activity of the clotting protein that is low in this condition, and menstrual blood loss is recorded using a simple diary that helps estimate the amount of blood lost each cycle. After the dosing phase, participants continue to be followed for a short time to ensure any delayed effects are captured. All procedures are designed to be as short and comfortable as possible.

Participants who have finished first‑line chemotherapy and are either in complete remission (no detectable cancer) or have stable disease are randomly assigned to one of the two groups. They take the study medication daily for a defined period while regular check‑ups, scans, and questionnaires about quality of life are performed. The study follows each participant for several years to record any return of cancer, new health problems, or death, and the information is used to compare the two treatment approaches.

The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

The purpose of the study is to evaluate safety and find the best dose of the new medicines when used alone or in combination. Participants receive an IV infusion, which means the medicine is delivered directly into a vein, and they swallow tablets on a regular schedule. Treatment cycles are repeated every few weeks, and patients return to the clinic for regular check‑ups, blood tests, and simple examinations to watch for any side effects.

The purpose of the study is to evaluate how the drug affects heart blood flow and tissue characteristics over short and long periods. Participants will receive the medication and undergo a series of heart scans using cardiovascular magnetic resonance (CMR) imaging, a type of MRI that creates detailed pictures of the heart. The scans will measure the myocardial perfusion reserve, which reflects the ability of heart muscle to receive blood, as well as other imaging markers such as tissue signals called T1, T2 and the amount of space outside cells called extracellular volume (ECV) mapping, and a technique called Late Gadolinium Enhancement (LGE) that shows scar tissue. Additional measurements will look at how much work the heart does each beat (stroke work), how efficiently it pumps (ventricular efficiency), its ability to contract (contractility), and the stiffness of the arteries (arterial elastance) using a pressure‑volume analysis (P‑V‑loop‑analysis). Blood flow patterns will also be examined with a technique called 4D flow‑analysis. The size of the heart muscle (myocardial mass) and the volume of the upper left chamber (left atrial volume) will be tracked.

The study will last several years, with participants returning for follow‑up scans at about three months, one year, and two years after starting treatment. Each visit will include the imaging procedures and safety checks, while the medication will be taken daily throughout the study period.

The purpose of the trial is to compare the effect of adding the new drug to usual treatment versus adding a placebo. Patients receive a combination of chemotherapy that may include irinotecan, oxaliplatin, paclitaxel albumin-bound, gemcitabine, fluorouracil, and calcium folinate hydrate. The oral study medication or the placebo is taken each day, while the chemotherapy drugs are given through an IV infusion on scheduled days.

Participants are randomly assigned to one of the two groups and neither they nor the doctors know which group they are in. Treatment cycles are repeated every few weeks, with regular visits for drug administration, blood tests, and imaging scans to check the tumor. The study continues until the disease progresses, side effects require stopping treatment, or a predefined period of follow‑up is completed.

The purpose of the study is to watch for any long‑term safety concerns, specifically the chance of developing malignancy caused by insertional oncogenesis, a process where the therapy’s genetic material might unintentionally trigger cancer. After receiving the infusion, participants will have regular sample collections over many years so doctors can check for signs of cancer or unusually high levels of altered cells. This monitoring helps ensure that any potential risks are identified early while the treatment’s benefits continue to be evaluated.

The purpose of the study is to evaluate whether Orelabrutinib can delay the worsening of disability compared with placebo. Participants will receive the assigned tablet each day for several years and will attend regular clinic visits where their ability to perform everyday tasks is checked and brain scans using MRI are performed to look for new lesions. The study will track how long it takes before a confirmed increase in disability occurs and will record any safety concerns throughout the trial.

Participants will receive a series of study visits over about two years. During the visits, the assigned treatment (either the medicine or the control solution) is administered by IV infusion at set intervals, and simple tests of thinking, memory and daily functioning are performed to check for any changes. Safety checks, such as blood tests and heart monitoring, are also done regularly to ensure the treatment is well tolerated. The overall design of the trial keeps both the participants and the study staff unaware of which treatment is being given, to provide an unbiased comparison.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The main goal of the study is to see whether a single dose of the medicine is safe and whether it can raise protein levels to a normal range, with some participants receiving a second dose later to assess longer‑term effects. Participants will receive the infusion, then attend regular visits over several months during which blood samples and simple health checks are performed.

Researchers will watch for any side effects, measure the amount of the protective protein in the blood, and test how well it works using a laboratory test called a elastase inhibition assay. They will also check lung function and liver health through routine exams and questionnaires to understand how the treatment impacts overall well‑being.

The purpose of the study is to evaluate the long‑term outcomes and safety of repeated adjuvant (additional) treatment with rituximab in this condition. Participants receive two infusions several weeks apart and are then followed for several months with regular clinic visits to check how they feel and to monitor any side effects.

During the follow‑up, doctors use simple rating scales such as the Clinical Global Impression – Improvement, which measures how much a person’s symptoms have gotten better, and the Clinical Global Impression – Severity, which rates how serious the illness is. Patients also complete short questionnaires about their overall health, daily functioning, and any changes in blood tests that may show immune system activity. Family members may be asked to give their view of any improvement as well.

During the scan, a short‑acting medicine is given through an IV to make the heart work a little harder, allowing doctors to see how the blood vessels respond. The medicines used are Adenosine and regadenoson, both of which safely cause a temporary rise in heart workload. A small amount of a harmless radioactive substance, O15-water, is also injected so the scanner can create detailed pictures of blood flow. The amount of blood moving through the heart muscle is expressed as MBF, which helps identify areas that may not be getting enough oxygen.

The purpose of the study is to find specific numbers that can predict the chance of future major heart problems, known as MACE. Participants undergo the PET scan with the stress medicines, then are followed for several years while information about any heart attacks, deaths, or related events is recorded. This follow‑up helps determine which scan results are linked to higher or lower risk.

After completing an earlier trial, participants may stay in the study and keep taking the medicine each day. They will visit the clinic at regular intervals where doctors will check their health, run blood tests, and ask them to fill out several questionnaires. These include a movement assessment called MDS-UPDRS, a short thinking test known as MoCA, a severity rating questionnaire (CISI-PD), a quality‑of‑life survey (PDQ-8), an anxiety and depression screen (HAD), and a questionnaire about other symptoms (NMSQ). Any side effects or abnormal lab results will be recorded, and the safety information will be compared with data from the earlier study’s active and placebo groups.

The main aim is to see how the level of a protein called neurofilament light chain in the cerebral spinal fluid changes over time when patients switch from Rituximab to Tolebrutinib compared with staying on Rituximab. Neurofilament light chain is a substance that can rise when nerve fibers are damaged, so measuring it helps understand disease activity.

Participants will be assigned to either continue receiving Rituximab or start taking Tolebrutinib, and they will be followed for up to two years. During this period, regular clinic visits will include blood draws, occasional spinal fluid collection, and standard brain scans to monitor any changes. The study does not involve any experimental procedures beyond the approved medications and routine testing.

The purpose of the trial is to evaluate the safety and efficacy of the new combination therapy. Over a period of about four weeks, subjects will take the study medication once daily, while other participants receive a matching placebo. Safety will be monitored through reports of any side effects, regular blood tests, standard 12‑lead ECG recordings to check heart rhythm, and measurements of Sweat chloride levels, which reflect how the disease is affecting the body.

Effectiveness will be assessed by measuring lung function using the percent predicted forced expiratory volume in one second (ppFEV1) and by having participants complete a disease‑specific questionnaire that evaluates breathing symptoms (CFQ R). The study involves several clinic visits for these tests and for overall health checks.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The main aim is to see if the drug is safe and can shrink or stop the growth of these cancers. Children will receive the medicine in a series of visits where doctors check for side effects, adjust the dose if needed, and use simple scans to see whether the tumor is getting smaller. The study follows participants for several months to record any problems and to determine whether the cancer responds, using terms like “objective response rate” (the percentage of children whose tumors shrink) and “disease control” (tumors that stay the same size or get smaller).

People in the study are placed into one of two groups. One group has the blood flow checked with indocyanine green fluorescence imaging, which means the dye is used so the surgeon can see how blood moves through the flap. The other group is checked with standard clinical assessment, which means the usual way of judging the flap during surgery. After the operation, the flap is followed for a short time to see how it heals and whether any further treatment is needed.